Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 June 2025 | Story Vuyelwa Mbebe and Aimee Barlow | Photo Supplied
KovsieCricket
From left to right: Xander Snyders, President: Free State Cricket Union; Rocky le Roux, Head of KovsieCricket at the UFS; and Donavin George, Mangaung Cricket Association Chairperson.

The University of the Free State’s (UFS) KovsieCricket club was honoured with two of the most significant awards at the recent Mangaung Cricket Association Annual General Meeting (MCA AGM).

First, KovsieCricket was crowned MCA Premier League Champions, marking a remarkable twelfth consecutive title in the region’s top league. Later, the club was named the Best Run Cricket Club in the Free State, a recognition that goes beyond match victories.

The MCA AGM, which reflects on the regional cricketing year, this year included key updates from MCA Chairperson Donavin George, a review of the season’s performance, and the election of the executive committee for the new term. The AGM also celebrates excellence, dedication, and growth within the sport during the preceding year.

Rocky le Roux, Head of Cricket at the UFS, reflected on the evening’s achievements by attributing them to the unified effort of everyone involved in the club. “These accolades are the result of unwavering dedication from our players, coaches, management, and support staff,” he said. “Our student-athletes lay the foundation with their performances, but none of this would be possible without the people working tirelessly behind the scenes. Teamwork, long-term planning, and a shared vision have allowed us to achieve this consistency.”

The Best Run Cricket Club award serves as a powerful validation of the systems and values in place at KovsieCricket, Le Roux said, adding that awards of these types are not only a source of pride but are instrumental in attracting top talent from around the country. “They show young cricketers that KovsieCricket is a place where they can grow, compete, and thrive – not just on the field, but as professionals and leaders.”

With regional dominance firmly established, KovsieCricket’s sights are now set on national excellence. Le Roux believes that becoming the best cricket club in South Africa is a realistic goal, but one that will require strategic growth in several key areas. He emphasised the need for permanent, experienced coaches to guide development, an even stronger recruitment network, facilities that meet national standards, and a culture of belonging that inspires players to invest fully in the club. He also stressed that consistent exposure to higher levels of competition and a focus on mental resilience will be critical in the journey ahead.

As KovsieCricket celebrates these milestones, Le Roux extended heartfelt gratitude to those who make the journey possible. He acknowledged Jerry Laka, Director of KovsieSport at the UFS, the KovsieSport team for their unwavering support, the players and coaches for their commitment to excellence, and Francis Marais, Supervisor of the sports grounds and grounds staff, for consistently preparing top-quality pitches. He also thanked the Mangaung Cricket Association for their continued efforts in running competitive leagues and providing the resources that help the game thrive in the Free State.

With another successful season behind it, KovsieCricket looks to the future with confidence and ambition. Trophies alone do not define the legacy they are building – rather, their culture of excellence, community, and purpose sets the standard for university cricket in South Africa and beyond.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept